GlassScriptPhysician profile
Keith A Thompson
NPI 1841246022
$2,257.70
in general payments reported to CMS, 2019-2025
36 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $28.72 · 2021: $295 · 2022: $431 · 2023: $185 · 2024: $155 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,043.45 |
| Education | $298.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $236.17 | 2021-2025 | |
| Seagen INC. | $213.84 | 2022-2025 | |
| Exelixis INC. | $207.60 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $200.09 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $197.48 | 2019-2025 | |
| Janssen Biotech, INC. | $152.14 | 2019-2025 | Tecvayli, Carvykti, Darzalex |
| Eisai INC. | $143.27 | 2021-2025 | |
| Abbvie INC. | $107.30 | 2022-2025 | Venclexta |
| Astrazeneca Pharmaceuticals LP | $94.86 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $68.63 | 2020-2022 | |
| Incyte Corporation | $68.02 | 2021-2025 | Monjuvi, Zynyz |
| Bayer Healthcare Pharmaceuticals INC. | $64.73 | 2025 | |
| Celgene Corporation | $58.47 | 2021-2023 | Reblozyl |
| Taiho Oncology, INC. | $34.10 | 2025 | |
| Array Biopharma INC | $33.23 | 2024-2025 | Xalkori, Lorbrena, Braftovi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.75 | 2022 | |
| Novocure INC. | $31.34 | 2025 | Optune Lua (Novottf-200t) |
| Pharmacyclics LLC, An Abbvie Company | $27.32 | 2022 | |
| Lilly USA, LLC | $26.54 | 2025 | Jaypirca, Verzenio |
| Ferring Pharmaceuticals INC. | $25.15 | 2025 | Adstiladrin |
| Gilead Sciences, INC. | $24.74 | 2021-2022 | |
| Genzyme Corporation | $22.58 | 2023 | |
| Genmab U.S., INC. | $18.13 | 2025 | Tivdak |
| Sumitomo Pharma America, INC. | $17.45 | 2024 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $16.79 | 2022 | |
| Stemline Therapeutics INC. | $16.75 | 2020 | |
| Deciphera Pharmaceuticals INC. | $14.93 | 2022 | |
| Glaxosmithkline, LLC. | $14.64 | 2023 | Zejula, Jemperli |
| Dentsply Sirona INC | $14.11 | 2023 | Aquasil Ultra+ Digit Smart Wetting Impression Material |
| Beigene USA, INC. | $12.65 | 2021 | |
| Aveo Pharmaceuticals, INC. | $12.53 | 2022 | |
| Kite Pharma, INC. | $12.19 | 2021 | |
| Epizyme, INC. | $12.04 | 2021 | |
| Morphosys, US INC. | $11.54 | 2021 | |
| Astellas Pharma US INC | $10.91 | 2019 | |
| Clovis Oncology, INC. | $3.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.